Kinetic and dynamic data of analgesics and NSAIDs drugs reduce 10X uncertainty factors

Human and Ecological Risk Assessment (HERA)

Volumn 3, Issue 4, 1997, Pages 567-578

  Kadry, Abdelrazak M ^a   Suh, Duck H ^a   Abdel Rahman, Mohamed S ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Nsaids; Pharmacodynamics; Pharmacokinetics; Uncertainty factor

Indexed keywords

EID: 21944450648     PISSN: 10807039     EISSN: None     Source Type: Journal    
DOI: 10.1080/10807039709383712     Document Type: Article

References (16)

1. REFERENCES Advenier, C., Roux, A., Gobert, G., Massias, P., Varoquaux, O., and Flouvat, B.1983. Pharmacokinetics of ketoprofen in the elderly. Br. J. Pharmacol, 16, 65-70.
2. Aw, T.Y., Shan, X., Sillau, A. H., and Jones, D.P. 1991. Effect of chronic hypoxia on acetaminophen metabolism in the rat. Biochen. Pharmacol. 42, 5, 1029-1038.
3. Barnes, D.G. and Dourson, M. 1988. Reference dose (RfD): Description and use in health risk assessments. Regal. Toxicol. Pharmacol. 8, 471-486.
4. Beaulac-Baillargeon, L. and Rocheleau, S. 1994. Paracetamol pharmacokinetics during the first trimester of human pregnancy. Eur. J. Clin. Pharmacol. 46, 451-454.
5. Borzelleca, J.F. 1991. Commentary on 'Assessment of safety/risk of chemicals: inception and evolution of the ADI and dose-response modeling procedures' by Frank C. Lu and Robert L. Sielken, Jr. Toxicol. Lett. 59, 1-4.
6. Brunborg, G., Holme, J.A., and Hongslo J.K. 1995. Inhibitory effects of paracetamol on DNA repair in mammalian cells. Mut. Res. 342, 157-170.
7. Conolly, R.B. 1995. Cancer and non-cancer risk assessment: not so different if you consider mechanisms. Toxicol. 102, 179-188.
8. Cuny, G., Royer, R. J., Mur, J. M., Serot, J. M., Faure, G., Netter, P., Maillard, A., and Penin, F. 1979. Pharmacokinetics of salicylates in elderly. Gerant. 25, 49-55.
9. Dahlin, D.C., Miwa, G.T., Lu, A.Y.A., and Nelson, S.D. 1984. N-acetyl-p- benzoquinone imine: a cytochrome P-450 mediated oxidation product of acetaminophen. Proc. Natl. Acad. Sci. 81, 1327-1331.
10. Dohi, M., Sakata, Y., Seki, J., Namikawa, Y., Fujisaki, J., Tanaka, A., Takasugi, H., Motoyama, Y., and Yoshida, K. 1993. The anti-platelet actions of FR122047, a novel cyclooxygenase inhibitor. Eur. J. Pharmacol. 243, 179-184.
11. Dourson, M.L., Felter, S.P., and Robinson, D. 1996. Evolution of science-based uncertainty factors in noncancer risk assessment. Regul. Toxicol. Pharmacol. 24, 108-120.
12. Dybing, E., Holme, J.A., Gordon, W.P., Soderlund, E.J., Dahlin, D.C., and Nelson S.D. 1984. Genotoxicity studies with paracetamol, Mut. Res. 138, 21-32.
13. Foster, R. T. and Jamali, F. 1988. Stereo selective pharmacokinetics of ketoprofen in the rat. Drug Metab. Dispos. 16, 4, 623-626.
14. Fu, C. J., Melethil, S., and Mason, W. D. 1991. The pharmacokinetics of aspirin in rats and the effect of buffer. J. Pharmacokin. Biopharm. 19, 2, 157-173.
15. Geisslinger, G., Schuster, O., Stock, K.-P., Loew, D., Bach, G.L., and Brune, K 1990. Pharmacokinetics of S(+)- and (R)- ibuprofen in volunteers and first clinical experience of S(+)- ibuprofen in rheumatoid arthritis. Eur.J. Clin. Pharmacol. 38, 493-497.
16. Hattis, D., Erdreich, L., and Ballew, M. 1987. Human variability in susceptibility to toxic chemicals - a preliminary analysis of pharmacokinetic data from normal volunteers. Risk Anal. 7, 4, 415-426.